sa¹ú¼Ê´«Ã½

Life Sciences

  • November 10, 2025

    Chancery Drops Claims In Murder-Linked Bio Co. Merger Fight

    The Delaware Chancery Court dismissed a biotech company's claims against the husband and investment vehicle of convicted fraudster Serhat Gumrukcu, whose murder-for-hire plot allegedly helped conceal past misconduct ahead of a 2018 merger.

  • November 10, 2025

    Catching Up With Delaware's Chancery Court

    Delaware's top court issued a flurry of rulings last week and heard arguments on recently passed legislation that expanded liability shields for some corporate acts while the Court of Chancery passed on another round of arguments over control of Caribbean broadcaster Caribevision.

  • November 07, 2025

    4th Circ. Opioid Case Brings Public Nuisance Back To The Fore

    The Fourth Circuit's ruling that upturned a lower court win for drug distributors in a battle with the West Virginia county at the epicenter of the opioid epidemic was a blast from the past from the fever pitch of courtroom battles over the national crisis just a few years ago.

  • November 07, 2025

    States Say Macquarie Not Applicable To NH High Court Case

    State securities regulators are urging New Hampshire's Supreme Court to uphold a fine against a medical device company whose leader was alleged to have misled investors about his prior legal issues, arguing that the case bears no resemblance to one ruled on by the U.S. Supreme Court last year.

  • November 07, 2025

    Sleep Apnea Device Co. Investor Says Rollout Was Botched

    Medical device company Inspire Medical Systems has been hit with a proposed investor class action alleging its shares dropped by nearly a third of their value after the public learned it concealed low demand and rollout shortcomings associated with its newest sleep apnea device.

  • November 07, 2025

    Spurned Pfizer Turns To Antitrust Law To Reclaim Biotech

    What may be a first-of-its-kind lawsuit is playing out as Pfizer Inc. turns to antitrust law to keep Novo Nordisk from usurping its bid for Metsera.

  • November 07, 2025

    Canadian Co. Blocked From Using 'Deep Cleansing Oil' Brand

    A Pennsylvania federal judge has permanently blocked a Canadian skincare company from infringing a competitor's trademark for "Deep Cleansing Oil," after it failed to respond to the case.

  • November 07, 2025

    Seattle Pot Shop Slapped With Site Tracking Pixel Privacy Suit

    A Seattle cannabis dispensary has been hit with a proposed class action in Washington federal court by a customer who claims the retailer shared his private information about medical marijuana appointments and pot purchases with Google and other third parties by using online browser tracking tools on its website.

  • November 07, 2025

    USPTO Extends Deadline For PTAB Institution Rules Feedback

    The U.S. Patent and Trademark Office has provided a 15-day extension for giving feedback on proposed rules that will likely reduce the institution of certain patent challenges at the Patent Trial and Appeal Board, with Director John Squires saying "now's the time" to finalize rulemaking on discretionary denial issues.

  • November 07, 2025

    Jury Clears Novo Nordisk Of Medicaid Fraud Over Blood Drug

    A Tacoma federal jury cleared Novo Nordisk on Friday of allegations that it defrauded Washington state's Medicaid and Medicare systems by paying kickbacks and promoting off-label use to illegally boost prescriptions of its hemophilia drug NovoSeven.

  • November 07, 2025

    Fla. Judge Sentences HIV Drug Fraudster To 8 Years In Prison

    A Florida federal judge on Friday sentenced a man to more than eight years in prison after he pled guilty to a wire fraud-related charge in connection to a roughly $100 million HIV medication fraud scheme, referencing the harm that called into question the nation's pharmaceutical drug supply. 

  • November 07, 2025

    Merck Wins PTAB Fight Over Blockbuster Drug, Again

    Another cancer treatment patent owned by Johns Hopkins University and challenged by a Merck & Co. Inc. subsidiary didn't pass muster with the Patent Trial and Appeal Board, which on Thursday invalidated seven claims in the patent that's at issue in a disagreement between the parties.

  • November 07, 2025

    Taxation With Representation: Kirkland, Cravath, Paul Weiss

    In this week's Taxation With Representation, consumer products giant Kimberly-Clark acquires Tylenol maker Kenvue, shale producers SM Energy and Civitas Resources announce a merger, and power management company Eaton buys Boyd Corp.'s thermal business.

  • November 07, 2025

    Laborie Buys Postpartum Bleeding Device For Up To $465M

    Medical technology company Laborie Medical Technologies, advised by Simpson Thacher & Bartlett LLP and Cooley LLP, unveiled plans Friday to acquire a postpartum uterine bleeding device from New Jersey-based healthcare company Organon for up to $465 million.

  • November 06, 2025

    Pair Of Health-Focused Startups Net $423M In Combined IPOs

    Two startups, spanning the diagnostics and biotechnology sectors, began trading on Thursday after raising a combined $423 million in initial public offerings, guided by three law firms, as more companies continue going public despite a historic government shutdown that has reduced staffing at the U.S. Securities and Exchange Commission.

  • November 06, 2025

    'Send A Message' To Novo Nordisk Over Kickbacks, Jury Told

    Counsel for a whistleblower claiming Novo Nordisk paid illegal kickbacks to boost off-label prescribing of its hemophilia drug NovoSeven urged jurors during closing arguments Thursday to "send a message" to the drugmaker, saying it defrauded Washington state's Medicaid and Medicare systems out of nearly $100 million.

  • November 06, 2025

    CareFirst Urges Ban On J&J Character Talk At Stelara Trial

    Health insurer CareFirst is asking a Virginia federal judge to bar Johnson & Johnson from promoting its "good character" to a jury that will weigh class claims of anticompetitive conduct and patent fraud to extend market protection on the blockbuster autoimmune drug Stelara.

  • November 06, 2025

    Lilly, Novo Nordisk Enter Obesity Drug Price Deal With Trump

    Pharmaceutical giants Eli Lilly and Novo Nordisk cut a deal with the Trump administration to slash the pricing of their popular weight loss drugs in the U.S., becoming the latest to enter "most-favored-nation" pricing agreements, the White House announced Thursday.

  • November 06, 2025

    Texas AG Wants To Halt Kenvue $400M Shareholder Pay

    Texas wants to block Johnson & Johnson consumer health spinoff Kenvue from paying $400 million to shareholders, calling it a "fraudulent transfer" amid the company, which makes Tylenol, facing "tens or hundreds of billions of dollars in liabilities" in the state's suit alleging the company hid the risk that acetaminophen could lead to autism.

  • November 06, 2025

    Fla. AG Says Planned Parenthood Lied About Abortion Drugs

    The Florida Attorney General sued Planned Parenthood on Thursday, alleging the reproductive healthcare nonprofit misrepresented the safety of abortion drugs to women in a mass marketing campaign.

  • November 06, 2025

    FDA Warns Companies About Illegal Marketing Of Botox

    The U.S. Food and Drug Administration has ordered the companies behind 18 websites to stop selling all Botox injectables to consumers that they have marketed as being able to treat chronic migraine, sweaty palms, overactive bladder and blepharospasm, or spasms that force one's eyelids closed.

  • November 06, 2025

    Squires Rebuffs Another 21 PTAB Petitions Without Comment

    U.S. Patent and Trademark Office Director John Squires issued a one-page order Thursday rejecting 21 patent challenges from companies including Microsoft, Apple and Google, continuing his new practice of summarily denying such petitions with no explanation.

  • November 06, 2025

    3rd Circ. Won't Revive Investors' Suit Over Viatris Sale

    The Third Circuit on Thursday upheld the dismissal of a proposed shareholder class action against pharmaceutical company Viatris, saying that investors hadn't plausibly alleged that they were misled about the future of the company's sold-off biosimilars business.

  • November 06, 2025

    Med Groups Call To Break Up 'Politicized' CDC Vax Committee

    A Massachusetts doctor and a group of public health trade associations want the federal government to break up a key vaccine committee tasked with nationwide vaccine policy, arguing in an amended lawsuit Thursday that the panel has been tainted with anti-vaccine sentiment.

  • November 06, 2025

    Edwards Defends $945M Heart Valve Deal From FTC Challenge

    Edwards Lifesciences urged a D.C. federal court to reject the Federal Trade Commission's bid to put its planned $945 million acquisition of JenaValve on hold, saying the deal will increase innovation and save the lives of thousands of people with a form of heart valve disease.

Expert Analysis

  • Vanda Ruling Opens Door For Contesting FDA Drug Denials

    Author Photo

    The D.C. Circuit's recent decision in Vanda Pharmaceuticals v. U.S. Food and Drug Administration creates new opportunities and considerations for drug companies navigating the FDA approval process, establishing that litigation is an option when the FDA refuses to hold a hearing, say attorneys at Polsinelli.

  • Series

    Law School's Missed Lessons: Mastering Time Management

    Author Photo

    Law students typically have weeks or months to prepare for any given deadline, but the unpredictability of practicing in the real world means that lawyers must become time-management pros, ready to adapt to scheduling conflicts and unexpected assignments at any given moment, says David Thomas at Honigman.

  • Rare Del. Oversight Ruling Sends Governance Wake-Up Call

    Author Photo

    An unusual ruling from the Delaware Court of Chancery recently allowed Caremark oversight claims to proceed against former executives of a company previously known as Teligent, sending a clear reminder that boards and officers must actively monitor and document oversight efforts when addressing mission-critical risks, say attorneys at WilmerHale.

  • How Hyperlinks Are Changing E-Discovery Responsibilities

    Author Photo

    A recent e-discovery dispute over hyperlinked data in Hubbard v. Crow shows how courts have increasingly broadened the definition of control to account for cloud-based evidence, and why organizations must rethink preservation practices to avoid spoliation risks, says Bree Murphy at Exterro.

  • Pharma Copay Programs Raise Complex Economic Questions

    Author Photo

    The growing prevalence of copay accumulator and maximizer programs in the pharmaceutical industry is drawing increased scrutiny from patients, advocacy groups, lawmakers and courts, bringing complex questions about how financial responsibility for prescription drug purchases is determined and complicating damages assessments in litigation, say analysts at Analysis Group.

  • State False Claims Acts Can Help Curb Opioid Fund Fraud

    Author Photo

    State versions of the federal False Claims Act can play an important role in policing the misuse of opioid settlement funds, taking a cue from the U.S. Department of Justice’s handling of federal fraud cases involving pandemic relief funds, says Kenneth Levine at Stone & Magnanini.

  • Beaming Up Lessons From William Shatner's Failed Patent Bid

    Author Photo

    In a tale that boldly goes where few celebrity inventors have gone before, William Shatner's unsuccessful attempt to patent a smartphone file organization system offers insights about potential pitfalls to avoid in patent applications, say attorneys at King & Spalding.

  • The Pros And Cons Of Levying Value-Based Fees On Patents

    Author Photo

    The potential for a recurring, value-based maintenance fee on patents, while offering some benefits, raises several complications, including that it would likely exceed the U.S. Patent and Trademark Office's statutory authority and reduce research and development activities in the U.S., says Sandip Patel at Marshall Gerstein.

  • Series

    Writing Musicals Makes Me A Better Lawyer

    Author Photo

    My experiences with writing musicals and practicing law have shown that the building blocks for both endeavors are one and the same, because drama is necessary for the law to exist, says Addison O’Donnell at LOIS Law.

  • Between The Lines Of EPO's Adoption Of Color Drawings

    Author Photo

    The European Patent Office's decision to accept patent drawings in color starting in October may enhance clarity in technical disclosures and streamline the examination process, and could also enable new patent filing strategies for international applicants, say attorneys at Miller Canfield.

  • What Prop 65 Ruling Means For Cosmetics, Personal Care Biz

    Author Photo

    A California federal court's recent decision on Proposition 65 warnings is good news for companies in the cosmetics and personal care space, as it will relieve businesses of the need to apply such warnings to products containing titanium dioxide and likely stop a wave of pending failure-to-warn litigation, say attorneys at Morgan Lewis.

  • Series

    Adapting To Private Practice: From Va. AUSA To Mid-Law

    Author Photo

    Returning to the firm where I began my career after seven years as an assistant U.S. attorney in Virginia has been complex, nuanced and rewarding, and I’ve learned that the pursuit of justice remains the constant, even as the mindset and client change, says Kristin Johnson at Woods Rogers.

  • 2 Fed. Circ. Rulings Underscore Patent Prosecution Pitfalls

    Author Photo

    Two recent patent decisions from the Federal Circuit, overturning significant judgments, serve as reminders that claim modifications and cancellations may have substantive effects on the scope of other claims, and that arguments distinguishing prior art and characterizing claims may also limit claim scope, say attorneys at Morgan Lewis.

  • Rebutting Price Impact In Securities Class Actions

    Author Photo

    Defendants litigating securities cases historically faced long odds in defeating class certification, but that paradigm has recently begun to shift, with recent cases ushering in a more searching analysis of price impact and changing the evidence courts can consider at the class certification stage, say attorneys at Katten.

  • 7 Document Review Concepts New Attorneys Need To Know

    Author Photo

    For new associates joining firms this fall, stepping into the world of e-discovery can feel like learning a new language, but understanding a handful of fundamentals — from coding layouts to metadata — can help attorneys become fluent in document review, says Ann Motl at Bowman and Brooke.

Want to publish in Law360?


Submit an idea

Have a news tip?


Contact us here
Can't find the article you're looking for? Click here to search the Life Sciences archive.